drugset
drugset / Trial / NCT06596057

Safety and Efficacy of CD19 CAR-T/CAR-NK Cells

NCT06596057 ↗

Phase 0 Active not recruiting 10 enrolled The Second Hospital of Shandong University
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety and efficacy of CD19 CAR-T/CAR-NK cells in patients with relapsed/refractory B-cell lymphoma and acute B-lymphoblastic leukemia.

Timeline

Start
2024-02-10
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CAR-T/CAR-NK cells Cell therapy 1e+06 cells/kg Intravenous
Subject CAR-T/CAR-NK cells Cell therapy 2e+06 cells/kg Intravenous

Indications

No indication recorded.